Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than ...

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to ...
Pharmaceutical Technology on MSN

Novartis targets undruggable cancers with $1.9BN Antares Therapeutics deal

Antares’ lead precision oncology programme is expected to enter the clinic in 2026.

Novartis (SWX:NOVN) Forms Antares Cancer Partnership And Expands Disability Access Efforts

Novartis (SWX:NOVN) announced a new oncology R&D partnership with Antares Therapeutics to pursue small molecule drugs for ...

Novartis and Antares to develop cancer drugs in a deal worth up to $1.9B

Novartis (NVS) stock is in focus as the company collaborates with Antares Therapeutics to develop cancer drugs in a deal ...

Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely

M upfront, up to $1.8B milestones, and what it signals for NVS amid patent cliffs. Click for this look at the deal.
Benzinga.com

Antares Pharma's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Antares Pharma ATRS earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.73 million in sales, a 1.12% ...